epiglucan and Obesity

The current review examines the totality of the evidence to determine if there exists a relationship between β-glucan and body weight and adiposity and whether such a relationship is a consistent, causal and plausible one. Observational studies suggest an association between oat (i.e., β-glucan) intake and reduced body weight, waist circumference and adiposity. High and moderate quality randomized controlled trials that were specifically designed to evaluate the efficacy of β-glucan on anthropometric outcomes were given the highest weight. Several of these studies indicated a causal relationship between β-glucan consumption and reduction in body weight, BMI, and at least one measure of body fat within diets that were not calorie-restricted. A review of additional animal and human evidence suggests multiple plausible mechanisms by which β-glucan may impact satiety perception, gastric emptying, gut hormones, gut microbiota and short chain fatty acids in the complex interplay of appetite and energy regulation.Supplemental data for this article is available online at http://dx.doi.org/10.1080/10408398.2021.1994523.

Topics: Adiposity; Animals; Avena; beta-Glucans; Body Weight; Edible Grain; Humans; Obesity

Dietary fiber supplementation has been studied as a promising strategy in the treatment of obesity and its comorbidities. A systematic review and meta-analysis were performed to verify whether the consumption of yeast beta-glucan (BG) favors weight loss in obese and non-obese rodents. The PICO strategy was employed, investigating rodents (Population), subjected to the oral administration of yeast BG (Intervention) compared to animals receiving placebo (Comparison), evaluating body weight changes (Outcome), and based on preclinical studies (Study design). Two reviewers searched six databases and the grey literature. We followed the PRISMA 2020 guidelines, and the protocol was registered on PROSPERO (CRD42021267788). The search returned 2467 articles. Thirty articles were selected for full-text evaluation, and seven studies remained based on the eligibility criteria. The effects of BG intake on body weight were analyzed based on obese (

Topics: Animals; beta-Glucans; Body Weight; Eating; Mice; Obesity; Rats; Saccharomyces cerevisiae; Weight Loss

Progress in genomic analysis has resulted in the proposal that the intestinal microbiota is a crucial environmental factor in the development of multifactorial diseases, such as obesity, diabetes, rheumatoid arthritis, and inflammatory bowel diseases represented by Crohn's disease and ulcerative colitis. Dysregulated gut microbiome contributes to the pathogenesis of such disorders; however, there are few effective treatments for controlling only disease-mediating bacteria. Here, we review current knowledge about the intestinal microbiome in health and disease, and discuss a regulatory strategy using a parenteral vaccine with emulsified curdlan and CpG oligodeoxynucleotides, which we have recently developed. Unlike other conventional injectable immunizations, our vaccine contributes to the induction of antigen-specific systemic and mucosal immunity. This vaccine strategy can prevent infectious diseases such as

Topics: Administration, Mucosal; Arthritis, Rheumatoid; Bacterial Vaccines; beta-Glucans; Diabetes Mellitus, Type 2; Dysbiosis; Gastrointestinal Microbiome; Humans; Immunity, Mucosal; Immunization Schedule; Immunization, Secondary; Immunoglobulin A; Inflammatory Bowel Diseases; Injections, Intramuscular; Intestinal Mucosa; Obesity; Oligodeoxyribonucleotides; Polysaccharides, Bacterial; Vaccines, Synthetic

Over the last few years the prevalence of overweight and obesity has increased, affecting in certain parts of the world more than half of the adult population. Obesity has been related to disorders such as type-2 diabetes, non-alcoholic fatty liver disease, and cardiovascular diseases, among others, which has made of obesity the second cause of preventable death, only behind smoking. Bearing this in mind, it is necessary to find new strategies to overcome overweight/obesity and its associated pathologies. In this context, nutraceuticals and dietary supplements have become interesting tools thanks to their composition, rich in bioactive compounds beneficial to health. Among bioactive compounds, this study will focus on β-glucans, a type of soluble dietary fiber, and hydroxycinnamic acids, a group of phenols. Both types of compounds show complex and multifactorial effects, acting as hypolipemic, hypoglycemic, antioxidant, prebiotic and satiating agents. They act by modulating different metabolic pathways, affecting the absorption and metabolism of lipids and carbohydrates, reducing oxidative damage, promoting the proliferation of beneficial bacterial species, and reducing dietary intake. It may be concluded that both beta-glucans and hydroxycinnamates have potential as a nutritional tool for the management of obesity and its associated metabolic dysfunctions.. Durante los últimos años se ha incrementado la incidencia de casos de sobrepeso/obesidad entre la población, afectando en ciertas partes del mundo a más de la mitad de la población adulta. La obesidad lleva asociada comorbilidades como la diabetes de tipo 2, la esteatosis hepática no alcohólica y las enfermedades cardiovasculares entre otras muchas, que la han convertido en la segunda causa de muerte evitable en el mundo, solo por detrás del tabaquismo. Ante esta nueva realidad se hace necesaria la búsqueda de nuevas estrategias para combatir el sobrepeso/obesidad y sus patologías asociadas. Los nutracéuticos o suplementos dietéticos se han convertido en una herramienta dietética de sumo interés gracias a su composición de compuestos bioactivos beneficiosos para la salud. De entre estos compuestos bioactivos, este estudio abordará en profundidad dos de ellos: una fibra soluble, los β-glucanos procedentes de la avena, y un tipo de compuesto fenólico, los hidroxicinamatos. Ambos tipos de compuestos presentan efectos complejos y multifactoriales al actuar como agentes hipolipemiantes, hipoglucemiantes, antioxidantes, prebióticos o saciantes. Ejercen su efecto modulando diferentes vías metabólicas que afectan tanto a la absorción como al metabolismo de los lípidos y los glúcidos, reduciendo el daño oxidativo, promoviendo la proliferación de especies bacterianas beneficiosas y reduciendo la ingesta dietética. Se puede concluir que tanto los beta-glucanos como los hidroxicinamatos presentan potencial como herramienta nutricional en el manejo de distintas disfunciones metabólicas asociadas a la obesidad.

Topics: Anti-Obesity Agents; beta-Glucans; Clinical Trials as Topic; Coumaric Acids; Dietary Supplements; Humans; Obesity

Obesity is a worldwide epidemic and a common medical condition associated with a variety of chronic diseases. Cereal beta-glucans are soluble fibers with potential health benefits. A number of randomized controlled trials (RCTs) have investigated the effect of cereal beta-glucan consumption on weight, but these results have not been summarized in a meta-analysis. The purpose of this study was to investigate the effect of cereal beta-glucan consumption on body weight, body mass index, waist circumference and a total energy intake.. Studies were identified using MEDLINE/PubMed, Scopus and Cochrane databases. Screening of relevant articles and references was carried out until December 2018. There were no language restrictions. This systematic review and meta-analysis was performed using the Preferred Items for Reporting of Systematic Reviews and Meta-Analyses (PRISMA) guidelines.. The findings of this study indicates that cereal beta-glucan consumption seems to decrease body weight and BMI, but has no effect on waist circumference and energy intake.

Topics: beta-Glucans; Body Mass Index; Body Weight; Edible Grain; Energy Intake; Humans; Obesity; Randomized Controlled Trials as Topic; Waist Circumference

Cereal-based food products have been the basis of the human diet since ancient times. Dietary guidelines all over the world are recommending the inclusion of whole grains because of the increasing evidence that whole grains and whole-grain-based products have the ability to enhance health beyond the simple provision of energy and nutrients. In this review we will examine the main chemical components present in whole grains that may have health enhancing properties (dietary fiber, inulin, beta-glucan, resistant starch, carotenoids, phenolics, tocotrienols, and tocopherols) and the role that whole grains may play in disease prevention (cardiovascular diseases and strokes, hypertension, metabolic syndrome, type 2 diabetes mellitus, obesity, as well as different forms of cancer). The knowledge derived from the functional properties of the different chemical components present in whole grains will aid in the formulation and development of new food products with health enhancing characteristics.

Topics: beta-Glucans; Cardiovascular Diseases; Carotenoids; Diabetes Mellitus, Type 2; Diet; Dietary Fiber; Edible Grain; Functional Food; Humans; Hydroxybenzoates; Hypertension; Inulin; Neoplasms; Obesity; Vitamin E

Dietary fiber may contribute to both the prevention and treatment of type 2 diabetes mellitus (T2DM). In epidemiological studies the intake of insoluble fiber, but not the intake of soluble fiber, has been inversely associated with the incidence of T2DM. In contrast, in postprandial studies, meals containing sufficiently quantities of beta-glucan, psyllium, or guar gum have decreased insulin and glucose responses in both healthy individuals and patients with T2DM. Diets enriched sufficiently in soluble fiber may also improve overall glycemic control in T2DM. Insoluble fiber has little effect on postprandial insulin and glucose responses. Fiber increases satiety. In some studies, insoluble fiber has been associated with less weight gain over time. Limited cross-sectional evidence suggests an inverse relationship between intake of cereal fiber and whole-grains and the prevalence of the metabolic syndrome. Although long-term data from trials focusing on specifically dietary fiber are lacking, meeting current recommendations for a minimum fiber intake of 25 g/d based on a diet rich in whole grains, fruits and legumes will probably decrease the risk of obesity, the metabolic syndrome and T2DM.

Topics: beta-Glucans; Cathartics; Diabetes Mellitus, Type 2; Dietary Fiber; Epidemiologic Studies; Galactans; Glucose; Humans; Insulin; Mannans; Metabolic Syndrome; Obesity; Plant Gums; Postprandial Period; Psyllium; Risk Factors

Topics: beta-Glucans; Cardiovascular Diseases; Coffee; Dietary Supplements; Humans; Lipids; Obesity; Overweight; Phenols; Polyphenols

Topics: Adolescent; Adult; Avena; beta-Glucans; Blood Pressure; Coffee; Comorbidity; Dietary Supplements; Female; Humans; Lipids; Male; Middle Aged; Obesity; Phenols; Plant Extracts; Young Adult

It is known that obesity has a multifactorial etiology that involves genetic and environmental factors. The WHO estimates the worldwide prevalence of 1.9 billion overweight adults and more than 650 million people with obesity. These alarming data highlight the high and growing prevalence of obesity and represent a risk factor for the development and aggravation of other chronic diseases, such as nonalcoholic fatty liver disease (NAFLD) that is frequently considered the hepatic outcome of type 2 diabetes. The use of non-pharmacological therapies such as food supplements, nutraceuticals, and natural integrative therapies has grown as an alternative tool for obesity-related diseases compared to conventional medications. However, it is a still little explored research field and lacks scientific evidence of therapeutic effectiveness. Considering this, the aim is to evaluate whether a new nutraceutical supplement composition can improve and supply essential mineral nutrients, providing an improvement of obesity-related metabolic and endocrine parameters.. Sedentary volunteers (women and men) with body mass index (BMI) ≤34.9 kg/m. In the anthropometric analysis, the waist circumference in middle abdomen (WC-mid) and waist circumference in iliac crest (WC-IC) were reduced. Also, the waist-to-height ratio (WHt R) and waist-to-hip ratio (WHR) seem to slightly decrease alongside the supplementation period with both nutraceutical supplements tested as well as transaminase enzyme ratio [aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio (AAR)], a known as a biomarker of NAFLD, and endocrine hormones cortisol and thyroid-stimulating hormone (TSH) at 90 and 180 days post-supplementation.. In a condition associated with sedentary and no nutritional intervention, the new nutraceutical supplement composition demonstrated the ability to be a strong and newfangled tool to improve important biomarkers associated with obesity and its comorbidities.

Topics: Adult; beta-Glucans; Biomarkers; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Humans; Male; Minerals; Non-alcoholic Fatty Liver Disease; Obesity; Prebiotics; Saccharomyces cerevisiae; Silybum marianum; Silymarin

Obesity is characterized by insulin resistance and low-grade systemic and adipose tissue (AT) inflammation. It remains unclear whether beneficial effects of weight loss are related to AT inflammation. We aimed to assess the effect of weight loss during low-calorie diet on insulin sensitivity, AT expression of genes associated with inflammation in young subjects with obesity. Furthermore, we estimated the effects of immunomodulatory (1, 3)(1, 6)-β-glucan (BG) on the above parameters.. The study group comprised 52 subjects with obesity. Twelve-week dietary intervention was applied, with randomization to receive or not 500 mg BG daily. Euglycemic hyperinsulinemic clamp, subcutaneous AT biopsy were performed before and after the program. Twenty normal-weight subjects, examined at baseline, served as a control group.. At baseline, obese subjects had lower insulin sensitivity, lower AT ADIPOQ, JAK1, and JAK2 expression and higher AT expression of LEP, IL6ST, STAT3, MIF, CCL2, MMP9, and IL18. Forty obese subjects completed dietary intervention program, which resulted in 11.3% weight loss and 27% increase in insulin sensitivity (both p < 0.0001). AT IL6R, IL6ST, JAK1, and JAK2 expression increased, whereas MIF, CCL2, MMP9, and IL18 gene expression did not change in response to weight loss. BG addition had no effect on any of the parameters studied.. Our data indicate that reduction in AT inflammation is not required for an improvement in insulin action during weight loss in subjects with uncomplicated obesity. BG does not have effects during dietary intervention.

Topics: Adult; beta-Glucans; Caloric Restriction; Female; Gene Expression; Humans; Inflammation; Insulin Resistance; Male; Obesity; Subcutaneous Fat; Weight Loss; Young Adult

Topics: Adult; Aged; beta-Glucans; Blood Pressure; Body Mass Index; Dietary Supplements; Double-Blind Method; Female; Humans; Inflammation; Interleukin-10; Interleukin-6; Male; Middle Aged; Obesity; Overweight; Time Factors; Tumor Necrosis Factor-alpha; Waist Circumference; Yeasts; Young Adult

Oats are high in soluble fibers and effective in reducing the risk of cardiovascular diseases (CVD). We assessed the effects of beta-glucan from oat bran on serum nitric oxide (NO) endothelial function in patients with hypercholesterolemia.. Sixty hypercholesterolemic patients were randomly divided to receive an experimental bread rich in beta-glucan from oat bran (intervention) or bread rich in wheat fiber (control) for four weeks. All subjects had the same diet for two-week baseline period and hypocaloric diet for four weeks of intervention. Serum NO concentration and flow-mediated dilation (FMD) were determined before and after the experiment.. Mean age of the participants was 51.1 ± 9.3 years and 65% (n = 39) were female. After intervention, serum NO concentration increased by 50.2 ± 19.8 μmol/lit in the intervention group (P = 0.017), but no change was observed in the control group (17.5 ± 27.5 μmol/lit; P = 0.530). No change of FMD was observed in the intervention (0.48 ± 0.78%; P = 0.546) or in the control group (0.59 ± 0.92%; P = 0.533).. Consumption of oat bread for four weeks increases serum NO concentration but has no effect on FMD. Further studies are warranted in this regard.

Topics: Adult; beta-Glucans; Bread; Cholesterol; Dietary Fiber; Endothelial Cells; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Obesity

White rice is a dominant grain-based food in Japan, but excess intake of polished rice may cause obesity. Barley is a grain-based food, similar to white rice, but it has the potential to control appetite and reduce energy intake. We investigated the effect of cooked white rice with high β-glucan barley on appetite and energy intake. The study was conducted as a randomized crossover design with twenty-one healthy Japanese women [mean ± standard deviation body mass index (BMI) 23.3 ± 0.7 kg/m(2)]. Subjects consumed a breakfast of cooked white rice with high β-glucan barley (BAR) or white rice (WR), followed by an ad libitum lunch and dinner. Energy intake was measured at the lunch and the dinner using plate waste. Subjects' perception scores on hunger, fullness, satiety, and prospective food consumption were assessed using a visual analogue scale (VAS) before and after the breakfast, lunch and dinner. BAR significantly reduced the VAS scores of hunger and prospective food consumption, and increased fullness before lunch compared to WR (P = 0.032, 0.019 and 0.038, respectively). Energy intake at lunch and the cumulative energy intake (lunch + dinner) subsequent to BAR consumption were significantly lower than WR (P = 0.035 and 0.021, respectively). BAR was able to modulate appetite and reduce energy intake. The combination of white rice with high β-glucan barley could play a beneficial role in preventing and treating obesity and other obesity-related metabolic diseases.

Topics: Adult; Appetite; beta-Glucans; Cooking; Dietary Fiber; Eating; Edible Grain; Energy Intake; Female; Hordeum; Humans; Hunger; Meals; Middle Aged; Obesity; Oryza; Prospective Studies; Satiation

Obesity is associated with a great diversity of diseases including non-alcoholic fatty liver disease. Our recent report suggested that oat, rich in beta-glucan, had a metabolic-regulating and liver-protecting effect in an animal model. In this study, we performed a clinical trial to further confirm the effect of oat. Subjects with BMI ≥27 and aged 18-65, were randomly divided into a control (n=18) and an oat-treated (n=16) group, taking a placebo or beta glucan-containing oat cereal, respectively, for 12 weeks. Our data showed that consumption of oat reduced body weight, BMI, body fat and the waist-to-hip ratio. Profiles of hepatic function, including AST, but especially ALT, were useful resources to help in the evaluation of the liver, since both showed decrements in patients with oat consumption. Nevertheless, anatomic changes were still not observed by ultrasonic image analysis. Ingestion of oat was well tolerated and there was no adverse effect during the trial. In conclusion, consumption of oat reduced obesity, abdominal fat, and improved lipid profiles and liver functions. Taken as a daily supplement, oat could act as an adjuvant therapy for metabolic disorders.

Topics: Abdominal Fat; Adipose Tissue; Adolescent; Adult; Aged; Avena; beta-Glucans; Body Fat Distribution; Body Mass Index; Dietary Carbohydrates; Dietary Supplements; Double-Blind Method; Humans; Liver; Middle Aged; Obesity; Phytotherapy; Plant Preparations; Seeds; Waist-Hip Ratio; Weight Loss; Young Adult

A high intake of whole grains containing soluble fiber has been shown to lower glucose and insulin responses in overweight humans and humans with type 2 diabetes.. We investigated the linearity of this response after consumption of 5 breakfast cereal test meals containing wheat and/or barley to provide varying amounts of soluble fiber, beta-glucan (0, 2.5, 5, 7.5 and 10 g).. Seventeen normoglycemic, obese women at increased risk for insulin resistance consumed 5 test meals within a randomized cross-over design after consuming controlled diets for 2 days. Blood samples for glucose and insulin response were obtained prior to and 30, 60, 120 and 180 min after consuming the test meals.. Consumption of 10 g of beta-glucan significantly reduced peak glucose response at 30 min and delayed the rate of glucose response. Area under the curve for 2 h-postprandial glycemic response was not affected by beta-glucan content. However, peak and area under the curve of insulin responses were significantly affected by the beta-glucan amount in an inverse linear relationship.. These data suggest that acute consumption of 10 g of beta-glucan is able to induce physiologically beneficial effects on postprandial insulin responses in obese women at risk for insulin resistance.

Topics: beta-Glucans; Blood Glucose; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Fiber; Dose-Response Relationship, Drug; Edible Grain; Energy Intake; Female; Glucose Tolerance Test; Hordeum; Humans; Insulin; Insulin Resistance; Middle Aged; Obesity; Risk Factors

A high intake of dietary fibre has been suggested to support the regulation of energy intake and satiety, which could contribute favourably to the increasing obesity problem.. To investigate the effects of three fibres differing in chemical and physical properties on perceived satiety and hunger-related attributes.. A total of 19 healthy volunteers, age 18-30, mean BMI 23.2 kg/m(2) participated in the study. Measurement of food and satiety-related perceptions with ten attributes was performed by using 10-unit graphic intensity scales during a 120 min period after the ingestion the sample. The attributes evaluated were satiety, hunger (unipolar and bipolar scale), appetite, fullness, desire to eat something/sweet/savoury/the sample food and thirst. The sample foods used were a beverage without fibre, a guar gum beverage, a wheat bran beverage, an oat beta-glucan beverage and wheat bread was used as the control. The fibre content of the samples was 0 g (beverage without fibre), 2.4 g (wheat bread), 7.8 g (guar gum) or 10.5 g (wheat bran and oat beta-glucan beverage) per 400 g/1,000 kJ portion.. The area under curve (AUC) for perceived satiety was higher (169 vs. 83 cm min; t test P = 0.026) and the desire to eat was lower (AUC -179 vs. -83 cm min; t test P = 0.008) for the guar gum beverage as compared to the beverage without fibre. Also the beverage with oat beta-glucan increased fullness and showed a trend of increasing perceived satiety and decreasing the desire to eat more than the beverage without fibre.. Our results support the idea that dietary fibre in beverages can enhance their perceived satiety and decrease the desire to eat more than a beverage without fibre.

Topics: Adolescent; Adult; Area Under Curve; Avena; beta-Glucans; Beverages; Cross-Over Studies; Dietary Fiber; Female; Galactans; Humans; Male; Mannans; Obesity; Perception; Plant Gums; Satiety Response; Solubility; Triticum; Viscosity; Young Adult

Peptide Y-Y (PYY) is an anorexigenic hormone implicated in appetite control, and beta-glucan is a fiber known to affect appetite. We hypothesized that plasma PYY levels would increase in overweight human adults consuming increasing doses of beta-glucan. The objective was to test whether the effect could be seen with beta-glucan delivered through extruded cereals containing a high beta-glucan oat bran with demonstrated high molecular weight and solubility. Fourteen subjects consumed a control meal and 3 cereals of varying beta-glucan concentration (between 2.2 and 5.5 g), and blood samples were collected over 4 hours. Analysis of raw PYY data showed a trend toward significant increases over 4 hours. An increasing dose of beta-glucan resulted in higher levels of plasma PYY, with significant differences between groups from 2 to 4 hours post test-meal. Data for the area under the curve analysis also approached significance, with post hoc analysis showing a difference (P = .039) between the control and the highest dose of beta-glucan (5.5 g). The PYY levels at 4 hours were significantly different between the control and high-dose meal test (P = .036). There was a significant dose response, with a positive correlation between the grams of beta-glucan and PYY area under the curve (r(2) = 0.994, P = .003). The optimal dose of beta-glucan appears to lie between 4 and 6 g, with the effects on PYY mediated by viscosity and concentration. Meal-test studies examining a range of hormones should measure hormones over a minimum of 4 hours and record meal intake for even longer time frames.

Topics: Adult; Area Under Curve; Avena; beta-Glucans; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Obesity; Peptide YY; Plant Preparations; Seeds

To assess the effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate homeostasis and biomarkers of oxidative stress.. A randomized, double-blind, controlled clinical trial.. The trial was conducted at two clinics.. Ninety-seven men and women with resting systolic blood pressure 130-179 mm Hg and/or diastolic blood pressure 85-109 mm Hg were randomly assigned to consume foods containing oat beta-glucan or control foods for 12 weeks. Resting blood pressures, insulin and glucose values before and after standard breakfast meals, and four biomarkers of oxidative stress were measured before and at the end of the treatment period.. Changes from baseline to week 12 in mean peak insulin and incremental area under the insulin curve differed significantly between groups (P=0.037 and 0.034, respectively), with the beta-glucan group showing declines and the control group remaining essentially unchanged. Blood pressure responses were not significantly different between groups overall. However, in subjects with body mass index above the median (31.5 kg/m(2)), both systolic (8.3 mm Hg, P=0.008) and diastolic (3.9 mm Hg, P=0.018) blood pressures were lowered in the beta-glucan group compared to controls. No significant differences in biomarkers of oxidative stress were observed between treatments.. The results of the present trial suggest beneficial effects of foods containing beta-glucan from oats on carbohydrate metabolism, and on blood pressure in obese subjects.

Topics: Area Under Curve; Avena; beta-Glucans; Biomarkers; Blood Glucose; Blood Pressure; Carbohydrate Metabolism; Dietary Fiber; Double-Blind Method; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Obesity; Oxidative Stress

Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; beta-Glucans; Cell Differentiation; Mice; Obesity; Oryza; Plant Extracts; PPAR gamma

Probiotics and prebiotics are commonly used to improve the gut microbiota. Since prebiotics can support the growth of probiotics, co-administration of these is called synbiotics. It has been demonstrated that obesity-induced gut dysbiosis can worsen inflammatory bowel disease symptoms. This study evaluated how modulation of gut microbiota with Schizophyllum commune-derived β-glucan (BG), probiotics (PRO), and synbiotics containing both BG and PRO (SYN) could improve the symptoms of obesity-associated colitis and hepatic manifestation.. Mice were fed a normal diet (ND), high-fat diet (HFD), and HFD with different additives (BG, PRO, and SYN) for 12 weeks, followed by 5 days of colitis induction. Mice were sacrificed before and after colitis induction. During the experiment, body weight, food and water consumption, and rectal bleeding were monitored. Proteins from the colon were subjected to western blotting, and serum biomarkers such as alanine transaminase, alkaline phosphatase, triglycerides, and total cholesterol were analyzed. Colon and liver samples were sectioned for histological analysis. The fecal microbiota was analyzed based on partial 16S rRNA gene sequences.. Although BG and PRO secured intestinal tight junctions, these two treatments did not modulate inflammatory cell infiltration and inflammatory markers (i.e., IL-6 and TNF-α). In contrast, SYN demonstrated stronger and broader effects in reducing colonic inflammation. While BG treatment increased the abundance of indigenous Lactobacillus, PRO treatment decreased bacterial diversity by suppressing the growth of several species of bacteria. SYN treatment groups, however, supported the growth of both indigenous and supplemented bacteria while maintaining bacterial diversity.. Obesity-associated colitis can be improved by modulating gut bacteria with β-glucan and probiotics. The co-administration of both outperformed β-glucan and probiotic treatment alone by fostering both indigenous and supplemented probiotic strains.

Topics: Animals; beta-Glucans; Colitis; Liver; Mice; Mice, Inbred C57BL; Obesity; Probiotics; RNA, Ribosomal, 16S; Synbiotics

Obesity is one of the most common nutritional disorders in dogs and cats and is related to the development metabolic comorbidities. Weight loss is the recommended treatment, but success is difficult due to the poor satiety control. Yeast beta-glucans are known as biological modifiers because of their innumerable functions reported in studies with mice and humans, but only one study with dogs was found. This study aimed to evaluate the effects of a diet supplemented with 0.1% beta-glucan on glucose, lipid homeostasis, inflammatory cytokines and satiety parameters in obese dogs. Fourteen dogs composed three experimental groups: Obese group (OG) with seven dogs with body condition score (BCS) 8 or 9; Lean group (LG) included seven non-obese dogs with a BCS of 5; and Supplemented Obese group (SOG) was the OG dogs after 90 days of consumption of the experimental diet.. Compared to OG, SOG had lower plasma basal glycemic values (p = 0.05) and reduced serum cholesterol and triglyceride levels. TNF-α was lower in SOG than in OG (p = 0.05), and GLP-1 was increased in SOG compared to OG and LG (p = 0.02).. These results are novel and important for recognizing the possibility of using beta-glucan in obesity prevention and treatment.

Topics: Animals; beta-Glucans; Diet; Dietary Supplements; Dog Diseases; Dogs; Insulin; Insulin Resistance; Obesity; Saccharomyces cerevisiae

Topics: Adolescent; Adult; beta-Glucans; Biological Availability; Coffee; Coumaric Acids; Female; Humans; Male; Middle Aged; Obesity; Overweight; Polyphenols; Young Adult

Emerging evidence suggests that insoluble dietary fiber prevents obesity by regulating gut dysbiosis. However, whether insoluble yeast β-glucan (IYG) has an anti-obesity effect is still unclear. Here, the impact and potential mechanism of long-term IYG supplementation on high-fat diet (HFD)-induced obesity were investigated. After 24 weeks of long-term supplementation, IYG ameliorated weight gain, dyslipidemia, systemic inflammation, glucose intolerance and insulin resistance in HFD-fed rats. In addition, HFD-induced gut dysbiosis and changed levels of short-chain fatty acids and lipopolysaccharide were restored by IYG. Meanwhile, HFD-induced downregulations of tight junction proteins and Mucin 2 as well as elevated gut permeability were recovered by IYG. IYG also mitigated HFD-induced colonic inflammation and oxidative stress. Moreover, antibiotic treatment abrogated the protective effect of IYG on obesity, indicating the important role of gut microbiota in IYG's effect. This study demonstrated that IYG, as a potential prebiotic, exhibited a protective effect on HFD-induced obesity.

Topics: Animals; beta-Glucans; Diet, High-Fat; Gastrointestinal Microbiome; Mice; Mice, Inbred C57BL; Obesity; Rats; Saccharomyces cerevisiae

Dietary fiber promotes a healthy gut microbiome and shows promise in attenuating the unfavorable microbial changes resulting from a high-fat/sucrose (HFS) diet. High-fiber diets consisting of oligofructose alone (HFS/O) or in combination with β-glucan (HFS/OB), resistant starch (HFS/OR), or β-glucan and resistant starch (HFS/OBR) were fed to diet-induced obese rats for 8 weeks to determine if these fibers could attenuate the obese phenotype. Only the HFS/O group displayed a decrease in body weight and body fat, but all fiber interventions improved insulin sensitivity and cognitive function. The HFS/O diet was the least effective at improving cognitive function and only the HFS/OB group showed improvements in glucose tolerance, thus highlighting the differential effects of fiber types. Hippocampal cytokines (IL-6, IL-10) were more pronounced in the HFS/OB group which coincided with the most time spend in the open arms of the elevated plus maze. All fiber groups showed an increase in beneficial Bifidobacterium and Lactobacillus abundance while the HFS group showed higher abundance of Clostridium. Fecal microbiota transplant from fiber-treated rats into germ-free mice did not alter body composition in the mice but did result in a higher abundance of Bacteroides in the HFS/O and HFS/OB groups compared to HFS. The HFS/OB recipient mice also had higher insulin sensitivity compared to the other groups. This study highlights the influence of dietary fiber type on metabolic and cognitive outcomes suggesting that the type of supplementation (single or combined fibers) could be tailored to specific targeted outcomes.

Topics: Animals; beta-Glucans; Cognition; Diet, High-Fat; Dietary Fiber; Insulin Resistance; Mice; Obesity; Rats; Resistant Starch; Sucrose

Gut microbiota alterations are associated with obesity and type 2 diabetes. Yeast β-glucans are potential modulators of the innate immune-metabolic response, by impacting glucose, lipid, and cholesterol homeostasis. The study examines whether yeast β-glucan interacts differentially with either an obese healthy or obese diabetic gut microbiome, to impact metabolic health through hepatic effects under high-fat dietary challenge.. Male C57BL/6J mice are pre-inoculated with gut microbiota from obese healthy (OBH) or obese type 2 diabetic (OBD) subjects, in conjunction with a high-fat diet (HFD) with/without yeast β-glucan. OBD microbiome colonization adversely impacts metabolic health compared to OBH microbiome engraftment. OBD mice are more insulin resistant and display hepatic lipotoxicity compared to weight matched OBH mice. Yeast β-glucan supplementation resolves this adverse metabolic phenotype, coincident with increasing the abundance of health-related bacterial taxa. Hepatic proteomics demonstrates that OBD microbiome transplantation increases HFD-induced hepatic mitochondrial dysfunction, disrupts oxidative phosphorylation, and reduces protein synthesis, which are partly reverted by yeast β-glucan supplementation.. Hepatic metabolism is adversely affected by OBD microbiome colonization with high-fat feeding, but partially resolved by yeast β-glucan. More targeted dietary interventions that encompass the interactions between diet, gut microbiota, and host metabolism may have greater treatment efficacy.

Topics: Animals; beta-Glucans; Diabetes Mellitus, Type 2; Diet, High-Fat; Gastrointestinal Microbiome; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Saccharomyces cerevisiae

Obesity is associated with other diseases such as diabetes and cancer. Botryosphaeran, a fungal (1→3)(1→6)-β-d-glucan, is described to present antimutagenic, hypoglycemic, hypocholesterolemic, and antitumor activities when administered by gavage over 15 days in rats and mice. Thus, the present study aims to analyze the metabolic effects of Botryosphaeran (12 mg/kg body weight/day) treatment over 30 days in obese Wistar male rats. Obesity was induced in the rats by a high-fat/high-sugar diet for 8 weeks. Control rats received a standard diet. On the 5th week, Botryosphaeran treatment commenced. Groups: control, obese, and obese+Botryosphaeran 30 days. In the 8th week, obesity was characterized. Feed intake, glucose and lipid profiles, glucose tolerance, and insulin sensitivity were analyzed. Obese rats showed accumulation of visceral adipose tissue, reduction of muscle mass, glucose intolerance, insulin resistance, hyperglycemia, and dyslipidemia. Botryosphaeran effectively reduced weight gains and the accumulation of retroperitoneal adipose tissue, corrected the levels of glucose, triglycerides, and very low-density lipoprotein-cholestrol, and improved insulin sensitivity. Treatment for 30 days was effective in maintaining the beneficial effects demonstrated by this β-glucan when administered for 15 days without promoting side effects. Treatment with (1→3)(1→6)-β- d-glucan presented anti-obesogenic and beneficial metabolic effects in Wistar rats; important for the treatment of obesity and its comorbidities.

Topics: Animals; beta-Glucans; Blood Glucose; Diet, High-Fat; Glucans; Glucose; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipoproteins, LDL; Male; Mice; Obesity; Rats; Rats, Wistar; Sugars; Triglycerides

Water-insoluble β-glucan has been reported to have beneficial effects on human health. However, no studies have thoroughly characterized the structure and function of water-insoluble β-glucan in oat bran. Thus, the structure and effect of water-insoluble β-glucan on weight gain and lipid metabolism in high-fat diet (HFD)-fed mice were analyzed. First, water-insoluble β-glucan was isolated and purified from oat bran. Compared with water-soluble β-glucan, water-insoluble β-glucan had higher DP3:DP4 molar ratio (2.12 and 1.67, respectively) and molecular weight (123,800 and 119,200 g/mol, respectively). Notably, water-insoluble β-glucan exhibited more fibrous sheet-like structure and greater swelling power than water-soluble β-glucan. Animal experiments have shown that oral administration of water-insoluble β-glucan tended to lower the final body weight of obese mice after 10 weeks treatment. In addition, water-insoluble β-glucan administration significantly improved the serum lipid profile (triglyceride, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels) and epididymal adipocytes size. What is more, water-insoluble β-glucan reduced the accumulation and accelerated the decomposition of lipid in liver. In conclusion, water-insoluble β-glucan (oat bran) could alleviate obesity in HFD-fed mice by improving blood lipid level and accelerating the decomposition of lipid.

Topics: Adipocytes; Animals; Avena; beta-Glucans; Cholesterol; Cholesterol, HDL; Diet, High-Fat; Dietary Fiber; Edible Grain; Humans; Lipid Metabolism; Lipids; Liver; Mice; Mice, Obese; Obesity; Spectroscopy, Fourier Transform Infrared; Triglycerides; Water

Emerging evidence links dietary fiber with altered gut microbiota composition and bile acid signaling in maintaining metabolic health. Yeast β-glucan (Y-BG) is a dietary supplement known for its immunomodulatory effect, yet its impact on the gut microbiota and bile acid composition remains unclear. This study investigated whether dietary forms of Y-BG modulate these gut-derived signals. We performed 4-wk dietary supplementation in healthy mice to evaluate the effects of different fiber composition (soluble vs. particulate Y-BG) and dose (0.1% vs. 2%). We found that 2% particulate Y-BG induced robust gut microbiota community shifts with elevated liver

Topics: Animals; beta-Glucans; Bile Acids and Salts; Bilophila; Cholesterol 7-alpha-Hydroxylase; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Insulin Resistance; Intestine, Small; Inulin; Liver; Male; Mice, Inbred C57BL; Obesity; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Yeasts

The effect of arabinoxylan (AX) combined with β-glucan and xyloglucan on lipid metabolism by regulating bile acids and gut microbiota was investigated in mice fed with high-fat diet. Fifty male ICR/KM mice were randomly divided into five groups: control diet (CON) group, high-fat diet (HFD) group, high-fat diet with AX (HFAX) group, high-fat diet with AX and β-glucan (HFAB) group, and high-fat diet with AX and xyloglucan (HFAG) group. After 8 weeks of feeding, the mice were sacrificed and samples were collected. In contrast to CON, HFD disturbed lipid metabolism, bile acids, and gut microbiota in mice. Mice in HFD group had increase in weight, blood lipids and liver fat, and circulating bile acid as well as abnormal liver tissue morphology and disordered gut microbiota. Compared with HFD, HFAB and HFAG mice had reduced body weight and cholesterol and triglyceride levels; Fxr was activated, Cyp7a1 was inhibited to reduce bile acids, the microbial species diversity increased, the number of beneficial bacteria increased, and the number of conditional pathogenic bacteria decreased. HFAG uniquely activated intestinal bile acid receptors (Fxr and Tgr5) and increased the abundance of Bacteroidetes and Akkermansia. In summary, the effect of AX compounded glucans (β-glucan or xyloglucan) on lipid metabolism was better than that of single AX by regulating bile acid metabolism and gut microbiota possibly due to the more complex chemical structure of combined polysaccharides.

Topics: Animals; beta-Glucans; Bile Acids and Salts; Body Weight; China; Cholesterol; Diet, High-Fat; Gastrointestinal Microbiome; Glucans; Lipid Metabolism; Lipid Metabolism Disorders; Liver; Male; Mice; Mice, Inbred ICR; Obesity; Xylans

The aim of this study was to investigate the underlying mechanism for the improvement of glucose tolerance following intake of high β-glucan barley (HGB) in terms of intestinal metabolism. C57BL/6J male mice were fed a fatty diet supplemented with HGB corresponding to 5% of dietary fiber for 83 days. An oral glucose tolerance test was performed at the end of the experimental period. The concentration of short-chain fatty acids (SCFAs) in the cecum was analyzed by GC-MS (gas chromatography-mass spectrometry). The mRNA expression levels related to L cell function in the ileum were measured by real-time PCR. Glucagon-like peptide-1 (GLP-1) levels in the portal vein and cecal content were assessed by enzyme-linked immunosorbent assay. GLP-1-producing L cells of the ileum were quantified by immunohistochemistry. HGB intake improved glucose tolerance and increased the cecal levels of SCFAs, acetate, and propionate. The number of GLP-1-positive L cells in the HGB group was significantly higher than in the control group. GLP-1 levels in the portal vein and cecal GLP-1 pool size in the HGB group were significantly higher than the control group. In conclusion, we report improved glucose tolerance after HGB intake induced by an increase in L cell number and subsequent rise in GLP-1 secretion.

Topics: Animals; beta-Glucans; Blood Glucose; Bodily Secretions; Cecum; Diet, High-Fat; Dietary Supplements; Fatty Acids, Volatile; Glucagon-Like Peptide 1; Glucose Tolerance Test; Hordeum; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity

The prebiotic effect of high β-glucan barley (HGB) flour on the innate immune system of high-fat model mice was investigated. C57BL/6J male mice were fed a high-fat diet supplemented with HGB flour for 90 days. Secretory immunoglobulin A (sIgA) in the cecum and serum were analyzed by enzyme-linked immunosorbent assays (ELISA). Real-time PCR was used to determine mRNA expression levels of pro- and anti-inflammatory cytokines such as interleukin (IL)-10 and IL-6 in the ileum as well as the composition of the microbiota in the cecum. Concentrations of short-chain fatty acids (SCFAs) and organic acids were analyzed by GC/MS. Concentrations of sIgA in the cecum and serum were increased in the HGB group compared to the control. Gene expression levels of

Topics: Animals; Bacterial Load; beta-Glucans; Body Weight; Carboxylic Acids; Cecum; Cytokines; Diet; Eating; Fatty Acids, Volatile; Feces; Flour; Gastrointestinal Microbiome; Gene Expression Profiling; Hordeum; Ileum; Immunoglobulin A, Secretory; Male; Mice; Mice, Inbred C57BL; Obesity; Organ Size; Prebiotics; Receptors, Polymeric Immunoglobulin; RNA, Messenger

Circadian disruption-induced metabolic syndrome (CDIMS) involves body weight gain, changes in blood profile and gut microbiota. In this study, CDIMS was induced by shifted light dark cycle (SLDC) in C57BL/6J mice. Dietary intervention by oral administration of oat β-glucan (a polymeric prebiotic) alleviated CDIMS when compared to chicory inulin/fructan (an oligomeric prebiotic) and melatonin (a chronobiotic). Oat β-glucan reversed the increase in body weight, liver weight-to-body weight ratio and plasma leptin concentration as well as restored glucose tolerance. In altering gut microbiota, oat β-glucan increased the species richness, reversed the populations of 7 bacterial genera and increased butyrate producers including Ruminococcaceae and Lachnospiraceae which enhance gut barrier protection and regulate glucose homeostasis. Correlation analysis demonstrated the linking of the alleviation of CDIMS by prebiotics and melatonin with different microbial metabolic pathways involved in energy metabolism, biosynthesis of metabolites, metabolism of cofactors and vitamins and endocrine synthesis.

Topics: Animals; Avena; beta-Glucans; Cichorium intybus; Circadian Rhythm; Gastrointestinal Microbiome; Inulin; Male; Melatonin; Metabolic Syndrome; Mice, Inbred C57BL; Obesity; Photoperiod; Prebiotics

The synergistic effects of Lactobacillus plantarum S58 (LP.S58) and hull-less barley β-glucan (β-G) on lipid accumulation in mice fed with a high-fat diet (HFD) were investigated. The body weight, serum lipid levels and lipid accumulation of adipose and liver tissues in the HFD-fed mice were inhibited after synergistic treatment with LP.S58 and β-G. In liver and adipose tissues, LP.S58 and β-G synergistically activated AMPK, reduced the expression of PPARγ, C/EBPα, SREBP-1c, FAS, SCD1 and LPL, and increased the expression of CPT-1 and HSL. The HFD-induced decreases in lipid metabolism-related hormones were reversed by LP.S58 and β-G. LP.S58 and β-G synergistically also increased the expression of colon tight junction proteins while suppressing systematic inflammation. LP.S58 and β-G ameliorated gut microbiological dysbiosis in HFD-fed mice. Correlations between serum parameters and gut microbiota were revealed. LP.S58 and β-G synergistically attenuated the HFD-induced lipid accumulation by activating AMPK signaling and regulating the gut microbiota.

Topics: Adenylate Kinase; Adipose Tissue; Animals; beta-Glucans; Diet, High-Fat; Dysbiosis; Gastrointestinal Microbiome; Inflammation; Lactobacillus plantarum; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Probiotics; Synbiotics

"Western" style dietary patterns are characterized by a high proportion of highly processed foods rich in fat and low in fiber. This diet pattern is associated with a myriad of metabolic dysfunctions, including neuroinflammation and cognitive impairment. β-glucan, the major soluble fiber in oat and barley grains, is fermented in the lower gastrointestinal tract, potentially impacting the microbial ecosystem and thus may improve elements of cognition and brain function via the gut-brain axis. The present study aimed to evaluate the effect of β-glucan on the microbiota gut-brain axis and cognitive function in an obese mouse model induced by a high-fat and fiber-deficient diet (HFFD).. After long-term supplementation for 15 weeks, β-glucan prevented HFFD-induced cognitive impairment assessed behaviorally by object location, novel object recognition, and nesting building tests. In the hippocampus, β-glucan countered the HFFD-induced microglia activation and its engulfment of synaptic puncta, and upregulation of proinflammatory cytokine (TNF-α, IL-1β, and IL-6) mRNA expression. Also, in the hippocampus, β-glucan significantly promoted PTP1B-IRS-pAKT-pGSK3β-pTau signaling for synaptogenesis, improved the synaptic ultrastructure examined by transmission electron microscopy, and increased both pre- and postsynaptic protein levels compared to the HFFD-treated group. In the colon, β-glucan reversed HFFD-induced gut barrier dysfunction increased the thickness of colonic mucus (Alcian blue and mucin-2 glycoprotein immunofluorescence staining), increased the levels of tight junction proteins occludin and zonula occludens-1, and attenuated bacterial endotoxin translocation. The HFFD resulted in microbiota alteration, effects abrogated by long-term β-glucan supplementation, with the β-glucan effects on Bacteroidetes and its lower taxa particularly striking. Importantly, the study of short-term β-glucan supplementation for 7 days demonstrated pronounced, rapid differentiating microbiota changes before the cognitive improvement, suggesting the possible causality of gut microbiota profile on cognition. In support, broad-spectrum antibiotic intervention abrogated β-glucan's effects on improving cognition, highlighting the role of gut microbiota to mediate cognitive behavior.. This study provides the first evidence that β-glucan improves indices of cognition and brain function with major beneficial effects all along the gut microbiota-brain axis. Our data suggest that elevating consumption of β-glucan-rich foods is an easily implementable nutritional strategy to alleviate detrimental features of gut-brain dysregulation and prevent neurodegenerative diseases associated with Westernized dietary patterns. Video Abstract.

Topics: Animals; beta-Glucans; Brain; Cognitive Dysfunction; Diet, High-Fat; Dietary Fiber; Gastrointestinal Microbiome; Male; Mice; Mice, Inbred C57BL; Obesity

We evaluated whether intake of β-glucan-rich barley flour affects expression levels of genes related to glucose and lipid metabolism in the ileum, liver, and adipose tissues of mice fed a high-fat diet. C57BL/6J male mice were fed a high-fat diet supplemented with high β-glucan barley, for 92 days. We measured the expression levels of genes involved in glucose and lipid metabolism in the ileum, liver, and adipose tissues using DNA microarray and q-PCR. The concentration of short-chain fatty acids (SCFAs) in the cecum was analyzed by GC/MS. The metabolic syndrome indices were improved by barley flour intake. Microarray analysis showed that the expression of genes related to steroid synthesis was consistently decreased in the liver and adipose tissues. The expression of genes involved in glucose metabolism did not change in these organs. In liver, a negative correlation was showed between some SCFAs and the expression levels of mRNA related to lipid synthesis and degradation. Barley flour affects lipid metabolism at the gene expression levels in both liver and adipose tissues. We suggest that SCFAs are associated with changes in the expression levels of genes related to lipid metabolism in the liver and adipose tissues, which affect lipid accumulation.

Topics: Adipose Tissue; Animals; beta-Glucans; Diet, High-Fat; Disease Models, Animal; Flour; Glucose; Hordeum; Ileum; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Oligonucleotide Array Sequence Analysis

Consumption of non-starch polysaccharides (NSP) is associated with reduced risk of obesity. This study aimed to compare the effects of cereals (oats) and legumes (soybean), rich in different classes of NSP, on appetite regulation and fat accumulation in rats. Soy pectin fermented more efficient than cereal arabinoxylan in rats. Soy pectin and oat β-glucan were utilized mainly in the caecum of rats. Only small amount of maltodextrin, cello-oligosaccharides and xylo-oligosaccharides were detected in the digesta. Caecal fermentation of soy pectin produced significantly higher concentration of short chain fatty acids (SCFAs) compared to the control. Retroperitoneal (RP) fat-pad weight was significantly lower for rats fed with soybean meal enriched diet than for controls. An inverse correlation between rat RP fat-pad weight and concentration (and proportion) of butyrate was observed. Consumption of soy pectin and oat β-glucan enriched foods to produce targeted SCFAs in vivo could be a potential strategy to lower fat mass accumulation and a potential tool to manage obesity.

Topics: Animals; Appetite Regulation; Avena; beta-Glucans; Body Weight; Cecum; Dietary Fiber; Digestion; Fermentation; Glycine max; Humans; Obesity; Pectins; Polysaccharides; Rats

Colorectal cancer (CRC) is the third most common tumor worldwide, and recent epidemiological studies have indicated that obesity contributes to the morbidity and mortality of CRC. Furthermore, obesity-related adipokines have been shown to be closely related to the incidence of CRC, but the underlying mechanisms are unclear. Here, we investigated the effects of high-fat diet-induced adipokines and cytokines on the development of CRC in vitro and in vivo. For the in vivo assays, we divided 2-week-old C57BL/6J-ApcMin/J male mice into three groups: normal-fat diet (ND), high-fat and high-sugar feed (HFHS), and high-fat and low-sugar feed (HFLS). After 1 week, all mice were injected with 20 mg·kg

Topics: Adipokines; Animals; beta-Glucans; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Cytokines; Diet, High-Fat; Dimethylhydrazines; Disease Progression; Male; Mice; Neoplasm Invasiveness; Obesity

β-(1,4)-d-Glucan with (1,2) and (1,6)-linked branches (short for β-glucan), extracted from Agaricus bisporus (Lange) Sing, had significant anti-obesity and lowering-fat effect. FITC-β-glucan was absorbed by adipocytes of zebrafish larvae when stained by Nile Red. β-Glucan decreased the adiposity mass, reduced the expression of ppar g, mtp, L-fabp, ifabp in ISH, which was coincident as the results of RT-PCT. β-Glucan lowered the level of C/EBP α, c SREBP1, LXR α, PPAR γ by WB analysis, which were accompanied by an increase level in LC3 II/LC3 I and a decline level in p62 in dose-dependent manner. This study explored the effect and mechanisms of Agaricus bisporus derived-β-glucan to regulate lipid metabolism and prevent lipid deposits, and provided the experimental data for its use in diet food and food addictive.

Topics: Adipocytes; Agaricus; Animals; Autophagy; beta-Glucans; Chickens; Down-Regulation; Egg Yolk; Obesity; PPAR gamma; Zebrafish

The prevalence of obesity and related disorders has vastly increased throughout the world and prevention of such circumstances thus represents a major challenge. Here, it has been shown that one protein-bound β-glucan (PBG) from the edible mushroom Coriolus versicolor can be a potent anti-obesity component.. PBG can reduce obesity and metabolic inflammation in mice fed with a high-fat diet (HFD). Gut microbiota analysis reveals that PBG markedly increases the abundance of Akkermansia muciniphila, although it does not rescue HFD-induced change in the Firmicutes to Bacteroidetes ratio. It appears that PBG alters host physiology and creates an intestinal microenvironment favorable for A. muciniphila colonization. Fecal transplants from PBG-treated animals in part reduce obesity in recipient HFD-fed mice. Further, PBG is shown to upregulate expression of a set of genes related to host metabolism in microbiota-depleted mice.. The data highlight that PBG may exert its anti-obesity effects through a mirobiota-dependent (richness of specific microbiota) and -independent (modulation of host metabolism) manner. The fact that C. versicolor PBGs are approved oral immune boosters in cancers and chronic hepatitis with well-established safety profiles may accelerate PBG as a novel use for obesity treatment.

Topics: Agaricales; Animals; Anti-Obesity Agents; beta-Glucans; Cytokines; Diet, High-Fat; Drug Evaluation, Preclinical; Fecal Microbiota Transplantation; Female; Fungal Proteins; Gastrointestinal Microbiome; Gene Expression Regulation; Inflammation; Mice, Inbred C57BL; Obesity; Verrucomicrobia

Sodium butyrate is well-known for its immune-modulatory properties. Studies until now only focused on the in vitro effects of butyrate or assessed local effects in the gut upon butyrate administration. In this trial, we studied the systemic anti-inflammatory effects induced by sodium butyrate supplementation in humans. Nine healthy (Lean) and ten obese (metabolic syndrome group, MetSyn) males were given 4 grams sodium butyrate daily for 4 weeks. PBMCs were isolated before and after supplementation for direct stimulation experiments and induction of trained immunity by oxidized low-density lipoprotein (oxLDL), β-glucan, or Bacillus Calmette-Guérin vaccine (BCG). Butyrate supplementation moderately affected some of the cytokine responses in the MetSyn group. In the direct stimulation setup, effects of butyrate supplementation were limited. Interestingly, butyrate supplementation decreased oxLDL-induced trained immunity in the MetSyn group for LPS-induced IL-6 responses and Pam3CSK4-induced TNF-α responses. Induction of trained immunity by β-glucan was decreased by butyrate in the MetSyn group for Pam3CSK4-induced IL-10 production. In this study, while having only limited effects on the direct stimulation of cytokine production, butyrate supplementation significantly affected trained immunity in monocytes of obese individuals with metabolic complications. Therefore, oral butyrate supplementation may be beneficial in reducing the overall inflammatory status of circulating monocytes in patients with metabolic syndrome.

Topics: Adult; Anti-Infective Agents; BCG Vaccine; beta-Glucans; Butyric Acid; Case-Control Studies; Cytokines; Drug Administration Schedule; Humans; Leukocytes, Mononuclear; Lipoproteins, LDL; Male; Middle Aged; Obesity; Young Adult

Whole-grain food (WGF) is well known for its anti-diabetic effect, and alleviation of obesity-induced insulin resistance (IR) might be one of the underlying mechanisms. In the current study, the effects of starch, as the main component in WGF, and β-glucan in a whole-grain-like structural form (WGLSF) on hepatic IR and glucose homeostasis were investigated using high-fat (HF)-induced obese C57BL/6J mice. After treatment for 8 weeks, the body weight gain and IR of the mice were significantly reduced. The hepatic Akt, the key component in insulin signaling, was activated, and the hepatic expression and protein levels of glucose-6-phosphatase (G-6-P) and phosphoenolpyruvate carboxykinase (PEPCK) were reduced. Moreover, WGLSF effectively reduced the hepatic levels of free fatty acids and the pro-inflammatory cytokines TNF-α, IL-6, and NF-κB. Additionally, the reduced level of the phosphorylated c-Jun-N-terminal kinases (JNK) indicated that WGLSF treatment might inactivate the JNK signaling, leading to improved hepatic IR. These results demonstrated that starch and β-glucan in a whole grain-like structural form have the potential as a dietary strategy to combat obesity-induced hepatic IR for improved health.

Topics: Animals; beta-Glucans; Diet, High-Fat; Glucose-6-Phosphatase; Humans; Insulin; Insulin Resistance; Interleukin-6; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Phosphoenolpyruvate Carboxykinase (ATP); Proto-Oncogene Proteins c-akt; Starch

Dietary intake of barley β-glucan (BG) is known to affect energy metabolism. However, its underlying mechanism remains poorly understood because studies have presented inconsistent results, with both positive and negative effects reported in terms of satiety, energy intake, weight loss, and glycemic control. The objective of this study was to clarify the physiological role underlying the metabolic benefits of barley BG using a mouse model of high fat diet (HFD)-induced obesity. Male 4-wk-old C57BL/6J mice were fed an HFD with 20% barley flour containing either high BG (HBG; 2% BG) or low BG (LBG; 0.6% BG) levels under conventional and germ-free (GF) conditions for 12 wks. In addition, mice were fed either an HFD with 5% cellulose (HFC; high fiber cellulose) or 5% barley BG (HFB; high fiber β-glucan) for 12 wks. Then, metabolic parameters, gut microbial compositions, and the production of fecal short-chain fatty acids (SCFAs) were analyzed. The weight gain and fat mass of HBG-fed mice were lower than those of control mice at 16-wk-old. Moreover, the secretion of the gut hormones PYY and GLP-1 increased in HBG-fed mice, thereby reducing food intake and improving insulin sensitivity by changing the gut microbiota and increasing SCFAs (especially, butyrate) under conventional condition. These effects in HBG-fed mice were abolished under GF conditions. Moreover, the HFB diets also increased PYY and GLP-1 secretion, and decreased food intake compared with that in HFC-fed mice. These results suggest that the beneficial metabolic effects of barley BG are primary due to the suppression of appetite and improvement of insulin sensitivity, which are induced by gut hormone secretion promoted via gut microbiota-produced SCFAs.

Topics: Actinobacteria; Animals; Appetite; beta-Glucans; Bifidobacterium; Diet, High-Fat; Fatty Acids, Volatile; Gastrointestinal Microbiome; Glucagon-Like Peptide 1; Hordeum; Intestinal Mucosa; Intestines; Male; Mice; Mice, Inbred C57BL; Obesity; Peptide YY

The aim of this study was to evaluate the effects of oat beta-glucan supplementation on metabolic, physiological, immunological and nutritional variables in adult dogs. Fourteen dogs were fed a control diet or a diet supplemented with 1% beta-glucan during 71 days. Serum concentrations of glucose, total cholesterol and lipoprotein fractions, as well as plasma concentrations of peptide YY and ghrelin, were determined. In addition, coefficient of total tract apparent macronutrient digestibility (CTTAD), food intake and fecal output, score, and pH were evaluated. For evaluation of immunological variables, serum concentrations of interleukin-4 and interferon gamma were determined on days 0, 57 and 71, which corresponded to blood collection prior to beta-glucan supplementation, and at 7 and 14 days post first and second dose of vaccination (Pneumodog®, Merial, Campinas, Brazil), respectively. Animals fed the supplemented diet showed (P<0.05) lower serum concentrations of total cholesterol and low and very low density lipoproteins, lower coefficients of total tract apparent digestibility of dry matter, organic matter, mineral matter and ether extract, higher fecal output and lower fecal consistency, as well as a tendency (P = 0.07) of decreasing the coefficient of total tract apparent digestibility of crude protein. Moreover, the supplemented diet resulted in lower number of red blood cells, hematocrit percentage and hemoglobin concentration 21 days post-vaccination as well as lower serum concentration of interleukin-4 seven days post-vaccination (P<0.05). It is concluded that oat beta-glucan extract can be used as a dietary supplement for dogs at a dose of 10 g/kg of food, being effective in reducing blood concentrations of total cholesterol, LDL-c and VLDL-c as well as CTTAD of nutrients, demonstrating a potential to be used in the feeding of obese animals. In addition, by reducing the predominance of a Th2 response, oat beta-glucan can positively modulate the vaccine response of animals.

Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Avena; beta-Glucans; Cholesterol; Dietary Supplements; Dogs; Eating; Feces; Interferon-gamma; Interleukin-4; Obesity; Vaccination

Previous studies suggest that dietary salecan (a water-soluble β-glucan) effectively reduces high-fat-diet-induced adiposity through disturbing bile-acid-promoted emulsification in mice. However, the effects of salecan on metabolic genes and metabolites involved in lipid accumulation are mostly unknown. Here, we confirmed that dietary 3% and 6% salecan for 4 weeks markedly decreased fat accumulation in liver and adipose tissue in high-fat-diet rats, displaying a decrease in mRNA levels of SREBP1-C, FAS, SCD1 and ACC1 involved in de novo lipogenesis and a reduction of levels of GPAT1, DGAT1 and DGAT2 related to triglyceride synthesis. Dietary salecan also increased the mRNA levels of PPARα and CYP7A1, which are related to fatty acid oxidation and cholesterol decomposition, respectively. In the

Topics: Adipose Tissue, White; Adiposity; Animals; Anti-Obesity Agents; Antioxidants; beta-Glucans; Biomarkers; Cell Size; Diet, High-Fat; Dietary Supplements; Gene Expression Profiling; Gene Expression Regulation; Lipogenesis; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Principal Component Analysis; Rats, Sprague-Dawley

β-glucan (BG) and mulberry have received increasing attention for their benefits as natural sources of metabolic health. In the current study, we investigated the synergetic beneficial effects of BG and mulberry leaf extract (MLE) in mice fed a high-fat diet (HFD). Male C57BL6 mice were fed a HFD for twelve weeks to induce significant obesity and insulin resistance. BG and MLE were administrated orally throughout the feeding period. The administration of BG resulted in a significant reduction in body weight gain, perirenal fat mass, fasting insulin, serum lipids, serum inflammation markers, and fatty liver, showing systemic health improvement. Likewise, the administration of MLE showed benefits similar to BG, with the exception of body weight gain. In addition to the systemic benefits, the combination of BG and MLE resulted in a synergetic improvement in insulin sensitivity. Meanwhile, only the combination of BG and MLE significantly enhanced liver GST (Glutathione S-Transferase) activity and CuZn-SOD (Superoxide dismutase (Cu-Zn)) activity, resulting in a significant reduction in GSH/GSSG (Glutathione disulfide) and reactive oxygen species (ROS) levels in the liver. These results further confirm the beneficial effects of BG and MLE on metabolic disorders and show that the combination of BG and MLE has synergetic effects.

Topics: Adiposity; Animals; Anti-Inflammatory Agents; Antioxidants; beta-Glucans; Biomarkers; Diet, High-Fat; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Lipids; Liver; Male; Mice, Inbred C57BL; Morus; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Plant Extracts; Plant Leaves; Time Factors; Weight Gain

Baker's yeast glucan (BYG) has been reported to be an anti-diabetic agent. In the work described herein, further study on the effect of orally administered BYG on glucose and lipid homeostasis in the livers of ob/ob mice was performed. It was found that BYG decreased the blood glucose and the hepatic glucose and lipid disorders. Western blotting analysis revealed that BYG up-regulated p-AKT and p-AMPK, and down-regulated p-Acc in the liver. Furthermore, RNA-Seq analysis indicated that BYG down-regulated genes responsible for gluconeogenesis (G6pase and Got1), fatty acid biosynthesis (Acly, Acc, Fas, etc.), glycerolipid synthesis (Gpam and Lipin1/2), and cholesterol synthesis (Hmgcr, Fdps, etc.). Additionally, BYG decreased glucose transporters SGLT1 and GLUT2, fat emulsification, and adipogenic genes/proteins in the intestine to decrease glucose and lipid absorption. All these findings demonstrated that BYG is beneficial for regulating glucose and lipid homeostasis in diabetic mice, and thus has potential applications in anti-diabetic foods or drugs.

Topics: Animals; beta-Glucans; Blood Glucose; Cholesterol; Diabetes Mellitus; Disease Models, Animal; Gluconeogenesis; Glucose; Glucose Transporter Type 2; Humans; Hypoglycemic Agents; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Saccharomyces cerevisiae; Sodium-Glucose Transporter 1

We investigated the effects of beta-glucans (Saccharomyces cerevisiae) ingestion on metabolic parameters of Wistar rats receiving high-fat diet. The experimental period was divided into two stages: in the first one, the animals were divided into two groups containing 12 animals each. The first group received commercial feed and the second received high-fat diet containing 20% of pork fat during 60 days. At the end of this period, body weight, blood glucose and Lee index were assessed. In the second stage, those 24 animals were redivided into four groups: (C) - control diet; (CB) - control diet and treated with Beta-glucan (BG); (O) - obese animals and (OB) - obese animals treated with BG. Animals from groups CB and OB received 30 mg/kg of BG dissolved in saline solution by gavage. Animals from groups C and O received only saline solution for 28 days. The design used was totally randomized in 2 × 2 factorial scheme. Data were submitted to analysis of variance (anova). Animals from OB group showed inferior levels (p < 0.05) of total cholesterol (13.33%), triacylglycerols (16.77%) and blood glucose (23.97%) when compared to the animals from group O. The use of BG has provided smaller increase in Lee index (p < 0.05), without promoting alteration in feed and water consumption, organs weight, HDL-C, LDL+VLDL-C, carcass composition, villus/crypt ratio, and pancreas, kidney and stomach histology. BG from S. cerevisiae promoted beneficial metabolic effects in rats receiving high-fat diet.

Topics: Animal Feed; Animals; beta-Glucans; Diet, High-Fat; Dietary Fats; Male; Obesity; Random Allocation; Rats; Saccharomyces cerevisiae

There is strong evidence indicating that gut microbiota have the potential to modify, or be modified by the drugs and nutritional interventions that we rely upon. This study aims to characterize the compositional and functional effects of several nutritional, neutraceutical, and pharmaceutical cardiovascular disease interventions on the gut microbiome, through metagenomic and metabolomic approaches. Apolipoprotein-E-deficient mice were fed for 24 weeks either high-fat/cholesterol diet alone (control, HFC) or high-fat/cholesterol in conjunction with one of three dietary interventions, as follows: plant sterol ester (PSE), oat β-glucan (OBG) and bile salt hydrolase-active Lactobacillus reuteri APC 2587 (BSH), or the drug atorvastatin (STAT). The gut microbiome composition was then investigated, in addition to the host fecal and serum metabolome.. We observed major shifts in the composition of the gut microbiome of PSE mice, while OBG and BSH mice displayed more modest fluctuations, and STAT showed relatively few alterations. Interestingly, these compositional effects imparted by PSE were coupled with an increase in acetate and reduction in isovalerate (p < 0.05), while OBG promoted n-butyrate synthesis (p < 0.01). In addition, PSE significantly dampened the microbial production of the proatherogenic precursor compound, trimethylamine (p < 0.05), attenuated cholesterol accumulation, and nearly abolished atherogenesis in the model (p < 0.05). However, PSE supplementation produced the heaviest mice with the greatest degree of adiposity (p < 0.05). Finally, PSE, OBG, and STAT all appeared to have considerable impact on the host serum metabolome, including alterations in several acylcarnitines previously associated with a state of metabolic dysfunction (p < 0.05).. We observed functional alterations in microbial and host-derived metabolites, which may have important implications for systemic metabolic health, suggesting that cardiovascular disease interventions may have a significant impact on the microbiome composition and functionality. This study indicates that the gut microbiome-modifying effects of novel therapeutics should be considered, in addition to the direct host effects.

Topics: Acetates; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; beta-Glucans; Butyrates; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Feces; Gastrointestinal Microbiome; Hemiterpenes; Limosilactobacillus reuteri; Male; Metabolome; Mice; Obesity; Pentanoic Acids; Probiotics

Translation of siRNA technology into the clinic is limited by the need for improved delivery systems that target specific cell types. Macrophages are particularly attractive targets for RNAi therapy because they promote pathogenic inflammatory responses in a number of important human diseases. We previously demonstrated that a multicomponent formulation of β-1,3-d-glucan-encapsulated siRNA particles (GeRPs) can specifically and potently silence genes in mouse macrophages. A major advance would be to simplify the GeRP system by reducing the number of delivery components, thus enabling more facile manufacturing and future commercialization. Here we report the synthesis and evaluation of a simplified glucan-based particle (GP) capable of delivering siRNA in vivo to selectively silence macrophage genes. Covalent attachment of small-molecule amines and short peptides containing weak bases to GPs facilitated electrostatic interaction of the particles with siRNA and aided in the endosomal release of siRNA by the proton-sponge effect. Modified GPs were nontoxic and were efficiently internalized by macrophages in vitro. When injected intraperitoneally (i.p.), several of the new peptide-modified GPs were found to efficiently deliver siRNA to peritoneal macrophages in lean, healthy mice. In an animal model of obesity-induced inflammation, i.p. administration of one of the peptide-modified GPs (GP-EP14) bound to siRNA selectively reduced the expression of target inflammatory cytokines in the visceral adipose tissue macrophages. Decreasing adipose tissue inflammation resulted in an improvement of glucose metabolism in these metabolically challenged animals. Thus, modified GPs represent a promising new simplified system for the efficient delivery of therapeutic siRNAs specifically to phagocytic cells in vivo for modulation of inflammation responses.

Topics: Amines; Animals; beta-Glucans; Cells, Cultured; Drug Delivery Systems; Genetic Therapy; Humans; Inflammation; Macrophages, Peritoneal; Male; Mice; Mice, Inbred C57BL; Obesity; Osteopontin; Peptide Fragments; Proteoglycans; RNA, Small Interfering

In this study, 2 β-glucans with different molecular weight were prepared and purified from hull-less barley bran. The aim was to evaluate their effects on the differentiation of 3T3-L1 pre-adipocytes. Results showed that barley β-glucans inhibited the differentiation of 3T3-L1 pre-adipocytes induced by differentiation medium in a dose-dependent manner, the suppressive effect of high-molecular-weight barley β-glucans (552 kDa, BGH) was stronger (P < 0.05) than that of low-molecular-weight barley β-glucan (32 kDa, BGL), evidenced by the significantly decrease (P < 0.05) of Oil-red O staining and intracellular triglyceride content in the mature adipocytes. Besides, gene expression analysis and Western Blot analysis revealed that both BGH and BGL inhibited the mRNA and protein levels of adipogenesis related transcription factors peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT-enhancer-binding protein α (C/EBPα) which are principal regulators of adipogenesis. Furthermore, the mRNA and protein expression levels of PPARγ target genes in adipose tissue including adipocyte fatty acid binding protein (ap2), lipoprotein lipase (LPL), uncoupling protein-2 (UCP-2), and glucose-transporter 4 (Glut4) in 3T3-L1 cells was also markedly downregulated (P < 0.05). These findings were anticipated to help develop barley β-glucans based functional food for the management of obesity.

Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Adipose Tissue; Animals; beta-Glucans; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Down-Regulation; Glucose Transporter Type 4; Hordeum; Ion Channels; Lipoprotein Lipase; Mice; Mitochondrial Proteins; Molecular Weight; Obesity; Plant Extracts; PPAR gamma; RNA, Messenger; Triglycerides; Uncoupling Protein 2

β-Glucans have been shown to reduce the risk of obesity and diabetes. However, they often contain diverse polysaccharides and other ingredients, leading to elusive experimental data and mechanisms. In this study, a pure β-glucan was obtained from the crude Baker's yeast polysaccharides for investigating its effect on the metabolic disorders in high-fat diet induced obese (DIO)/type 2 diabetic (T2D) mice and the underlying mechanism.. The Fourier transform infrared spectroscopy and nuclear magnetic resonance spectroscopy data indicated that the pure β-glucan (BYGlc) was a linear β-(1→3)-glucan. It was first found that the oral administration of BYGlc into T2D and DIO mice significantly downregulated the blood glucose through suppressing sodium-glucose transporter-1 expression in intestinal mucosa. Meanwhile, BYGlc promoted glycogen synthesis and inhibited fat accumulation in liver, and depressed macrophage infiltration and pro-inflammatory cytokines production measured by histochemistry/immunohistochemistry and ELISA. Additionally, BYGlc remarkably decreased Firmicutes population and increased the proportion of Akkermansia by 16S rDNA analysis.. BYGlc showed hypoglycemic activity accompanied by promotion of metabolism and inhibition of inflammation in T2D/DIO mice model. The hypoglycemic mechanisms were first declared to be through suppressing sodium-glucose transporter-1 expression and possibly associated with the altered gut microbiota.

Topics: Animals; beta-Glucans; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Female; Firmicutes; Gastrointestinal Microbiome; Hypoglycemic Agents; Inflammation; Intestinal Mucosa; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Rats; Rats, Sprague-Dawley; Saccharomyces cerevisiae; Sodium-Glucose Transporter 1; Verrucomicrobia

This study explored the dose-dependent effect of oat cereal β-glucan on improving metabolic indexes of obesity mice. C57-Bl mice were randomized to chow diet (N) group and high fat diet group and other three doses of oat β-glucan groups (low β-glucan, medium β-glucan, and high β-glucan). Energy intake, glucose, lipids, and appetite related hormones were tested. Dose-dependent relation was observed on oat β-glucan doses and body weight change, average energy intake, total cholesterol, HDL cholesterol, plasma neural peptide Y, arcuate neural peptide Y mRNA, and arcuate neural peptide Y receptor 2 mRNA level. Oat β-glucan helped to increase plasma peptide Y-Y and intestine peptide Y-Y expression in obesity mice.

Topics: Animals; Avena; beta-Glucans; Cholesterol, HDL; Cholesterol, LDL; Diet; Energy Intake; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Peptide YY; Satiation

Salecan is a recently identified water-soluble viscous extracellular β-1,3-D-glucan polysaccharide from an Agrobacterium species. It is a high-molecular-mass polymer (about 2 × 10⁶ Da) and composed of a linear chain of glucosyl residues linked through a repeat unit of seven β-(1,3) and two α-(1,3) glucosidic bonds. In the present study, we examined the effects of dietary Salecan fed at 2 and 5 % in a high-fat diet (64 % energy) in C57BL/6J mice. After 6 weeks, mice fed 2 and 5 % Salecan had significantly lower body weight, fat mass and percentage of body fat mass compared with those fed a high-fat cellulose (control) diet. Both the Salecan groups significantly and dose-dependently improved glucose tolerance, with a 9 and 26 % reduction of glucose AUC, respectively. Liver and adipose tissue weights were also significantly decreased by the Salecan treatment. Supplementation with 5 % Salecan led to lower serum TAG, total cholesterol (TC) and HDL-cholesterol (52, 18 and 19 %, respectively) and lower hepatic TAG by 56 % and TC by 22 % compared with the high-fat cellulose control group. Dietary Salecan intake caused an obvious elevation of fat in the faeces. Supplementation with Salecan disturbed bile acid-promoted emulsification and reduced the size of emulsion droplets in vitro. These results indicate that Salecan decreases fat absorption, improves glucose tolerance and has biologically important, dose-related effects on reducing high-fat diet-induced obesity.

Topics: Adiposity; Animals; Anti-Obesity Agents; beta-Glucans; Cell Size; Diet, High-Fat; Dietary Fats; Dietary Supplements; Emulsifying Agents; Feces; Female; Glucose Intolerance; Intestinal Absorption; Intra-Abdominal Fat; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Obesity; Organ Size; Solubility; Weight Gain

The soluble fiber β-glucan, a natural component of barley, has been shown to lower the postprandial glucose response and is thought to improve insulin resistance.. This study examined the effect of chronic consumption of the high β-glucan barley flour on glucose control, liver lipids and markers of muscle fatty acid oxidation in the Zucker diabetic fatty (ZDF) rat. Two groups of ZDF rats were fed diets containing either 6% β-glucan in the form of barley flour or cellulose as a control for 6 weeks. A group of Zucker lean rats served as a negative control.. The barley flour group had an increased small intestinal contents viscosity compared to the obese control group. After 6 weeks, the barley flour group had reduced glycated hemoglobin, lower relative kidney weights and a reduced area under the curve during a glucose tolerance test, indicating improved glucose control. Fasting plasma adiponectin levels increased in the barley flour group and were not different than the lean control group. ZDF rats on the barley flour diet had lower relative epididymal fat pad weights than the obese control and a greater food efficiency ratio. The barley flour group also had reduced liver weights and a decreased concentration of liver lipids. The barley flour group had significantly higher concentrations of muscle acylcarnitines, a metabolite generated during fatty acid oxidation.. These results show that chronic consumption of β-glucans can improve glucose control and decrease fatty liver in a model of diabetes with obesity.

Topics: Adiponectin; Animals; beta-Glucans; Blood Glucose; Body Weight; Carnitine; Cholesterol; Diabetes Mellitus, Type 2; Dietary Fiber; Disease Models, Animal; Fatty Acids, Nonesterified; Fatty Liver; Flour; Glucose Tolerance Test; Hordeum; Insulin; Insulin Resistance; Intestine, Small; Ketones; Liver; Obesity; Organ Size; Postprandial Period; Rats; Rats, Zucker; Thiobarbituric Acid Reactive Substances; Triglycerides

Obesity is rising at an alarming rate globally. Different fermentable carbohydrates have been shown to reduce obesity. The aim of the present study was to investigate if two different fermentable carbohydrates (inulin and β-glucan) exert similar effects on body composition and central appetite regulation in high fat fed mice.. Thirty six C57BL/6 male mice were randomized and maintained for 8 weeks on a high fat diet containing 0% (w/w) fermentable carbohydrate, 10% (w/w) inulin or 10% (w/w) β-glucan individually. Fecal and cecal microbial changes were measured using fluorescent in situ hybridization, fecal metabolic profiling was obtained by proton nuclear magnetic resonance ((1)H NMR), colonic short chain fatty acids were measured by gas chromatography, body composition and hypothalamic neuronal activation were measured using magnetic resonance imaging (MRI) and manganese enhanced MRI (MEMRI), respectively, PYY (peptide YY) concentration was determined by radioimmunoassay, adipocyte cell size and number were also measured. Both inulin and β-glucan fed groups revealed significantly lower cumulative body weight gain compared with high fat controls. Energy intake was significantly lower in β-glucan than inulin fed mice, with the latter having the greatest effect on total adipose tissue content. Both groups also showed an increase in the numbers of Bifidobacterium and Lactobacillus-Enterococcus in cecal contents as well as feces. β-Glucan appeared to have marked effects on suppressing MEMRI associated neuronal signals in the arcuate nucleus, ventromedial hypothalamus, paraventricular nucleus, periventricular nucleus and the nucleus of the tractus solitarius, suggesting a satiated state.. Although both fermentable carbohydrates are protective against increased body weight gain, the lower body fat content induced by inulin may be metabolically advantageous. β-Glucan appears to suppress neuronal activity in the hypothalamic appetite centers. Differential effects of fermentable carbohydrates open new possibilities for nutritionally targeting appetite regulation and body composition.

Topics: Adipocytes; Animals; Appetite Regulation; beta-Glucans; Bifidobacterium; Body Composition; Brain Mapping; Carbohydrates; Chromatography, Gas; Enterococcus; Fermentation; In Situ Hybridization, Fluorescence; Inulin; Lactobacillus; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C57BL; Obesity; Peptide YY; Radioimmunoassay

In this study we evaluated the effect of the administration of different soluble fiber enriched-diets on inflammatory and redox state of Zucker fatty rats. Four groups of ten 8 week-old female Zucker fatty rats were used. The four groups were respectively fed the following diets until the 15th week of life: standard diet (obese control), 10% high methoxylated apple pectin (HMAP)-, 5% soluble cocoa fiber (SCF)-, and 10% β-glucan-enriched diets. A group of Zucker lean rats fed the standard diet was also used as control for normal values of this rat strain. The plasma levels of tumoral necrosis factor-α (TNF-α), adiponectin, and malondialdehyde (MDA) were measured at the end of treatment. The reduced glutathione liver levels were also obtained at that moment. TNF-α plasma levels decreased somewhat in Zucker fatty rats fed the different fibers, and MDA plasma levels significantly decreased in these animals. Nevertheless, adiponectin plasma levels increased in the Zucker fatty rats fed the SCF enriched diet, but did not change in the HMAP and the β-glucan group. The Zucker fatty rats fed the different fiber showed a trend towards increased the reduced glutathione liver levels, but significant differences with obese control rats were only obtained in the β-glucan group. The results obtained in this study suggest that the intake of the different soluble fiber-enriched diets that we have evaluated could prevent and/or attenuate the inflammatory and/or the prooxidative state of the metabolic syndrome.

Topics: Adiponectin; Animals; beta-Glucans; Biomarkers; Cacao; Dietary Fiber; Female; Glutathione; Inflammation; Liver; Malondialdehyde; Malus; Obesity; Oxidative Stress; Pectins; Rats; Rats, Zucker; Tumor Necrosis Factor-alpha

This study tested the effects of (1→3),(1→4) β-D-glucan from oats, on activation of the gut-hypothalamic (PYY₃₋₃₆-NPY) axis, satiety, and weight loss in diet-induced obesity (DIO) mice. DIO mice were fed standard lab chow diets or varied doses of β-glucan for 6 weeks. Energy intake, satiety, body weight changes and peptide Y-Y₃₋₃₆ (PYY₃₋₃₆) were measured together with a satiety test and measurement of neuropeptide Y (NPY) mRNA expression in the hypothalamic arcuate nucleus (Arc). The average energy intake (-13%, p<0.05) and body weight gain was lower with increasing β-glucan over 6 wk with acute suppression of energy intake over 4 h. The highest β-glucan diet significantly increased plasma PYY₃₋₃₆, with suppression of Arc NPY mRNA.

Topics: Animals; Arcuate Nucleus of Hypothalamus; Avena; beta-Glucans; Body Weight; Diet; Dose-Response Relationship, Drug; Energy Intake; Gastrointestinal Tract; Male; Mice; Mice, Inbred C57BL; Neuropeptide Y; Obesity; Peptide Fragments; Peptide YY; RNA, Messenger; Satiety Response

Consumption of a diet high in barley beta-glucan (BG) has been shown to prevent insulin resistance. To investigate the mechanism for the effects of barley BG, three groups of male 7-wk-old C57BL/6J mice were fed high-fat diets containing 0, 2, or 4% of barley BG for 12 wk. The 2% BG and 4% BG groups had significantly lower body weights compared with the 0% BG group. The 4% BG group demonstrated improved glucose tolerance and lower levels of insulin-resistance index and glucose-dependent insulinotropic polypeptide. Consumption of the BG diet decreased hepatic lipid content. Mice on the BG diet also demonstrated decreased fatty acid synthase and increased cholesterol 7alpha-hydroxylase gene expression levels. The BG diet promoted hepatic insulin signaling by decreasing serine phosphorylation of insulin receptor substrate 1 and activating Akt, and it decreased mRNA levels of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. In summary, consumption of BG reduced weight gain, decreased hepatic lipid accumulation, and improved insulin sensitivity in mice fed a high-fat diet. Insulin signaling enhanced due to the expression changes of glucose and lipid metabolism genes by BG consumption. Consumption of barley BG could be an effective strategy for preventing obesity, insulin resistance, and the metabolic syndrome.

Topics: Animals; beta-Glucans; Body Weight; Dietary Fats; Fatty Liver; Gastric Inhibitory Polypeptide; Gene Expression Regulation, Enzymologic; Glucose Intolerance; Hordeum; Insulin Receptor Substrate Proteins; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Messenger; Seeds; Signal Transduction